Xeris Biopharma (NASDAQ:XERS) Director Marla Persky Sells 15,500 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Marla Persky sold 15,500 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $5.90, for a total transaction of $91,450.00. Following the sale, the director owned 126,500 shares in the company, valued at $746,350. This trade represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Up 0.5%

Shares of NASDAQ:XERS opened at $6.18 on Friday. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The firm has a market capitalization of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The firm’s 50-day moving average is $6.10 and its two-hundred day moving average is $6.59. Xeris Biopharma Holdings, Inc. has a 1 year low of $4.30 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on XERS. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xeris Biopharma has an average rating of “Hold” and a consensus price target of $10.80.

Hedge Funds Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Divisadero Street Capital Management LP acquired a new position in shares of Xeris Biopharma during the third quarter worth about $3,308,000. Apella Capital LLC boosted its holdings in Xeris Biopharma by 2,359.0% in the fourth quarter. Apella Capital LLC now owns 245,897 shares of the company’s stock valued at $1,930,000 after purchasing an additional 235,897 shares in the last quarter. Granahan Investment Management LLC acquired a new position in Xeris Biopharma in the third quarter valued at approximately $2,850,000. Vanguard Group Inc. boosted its holdings in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Xeris Biopharma in the third quarter valued at approximately $739,000. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.